BIRC5 and colonic neoplasm: These properties of BIRC5/survivin made it a subject of dendritic cell-based vaccination and anti-tumor sensitization protocols [30,31], which are to be tried out in clinical trials for patients with advanced solid tumors including BC, melanoma, glioma, and pancreatic and colon cancers.